Morgan Stanley analyst Judah Frommer raised the firm’s price target on Belite Bio (BLTE) to $201 from $191 and keeps an Overweight rating on the shares. The company’s Q4 update included narrowing timing for expected tinlarebant NDA submission to the FDA to Q2 and management reiterated expectations for a broad label, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio price target raised to $200 from $195 at BofA
- Tinlarebant De‑Risking Milestones and Rare-Disease Upside Support Buy Rating and $200 Price Target
- Midday Fly By: Markets bounce back following U.S.-Israeli attacks on Iran
- Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win
- Belite Bio sees Q4 adjusted EPS (38c), consensus (54c)